Cancer Diagnostics – News and Features

The objective of the extended collaboration is to develop DNA microarrays to detect genetic cancer markers.

Ciphergen and its collaborators will work together to further validate and characterize ovarian cancer biomarkers.

First year awards totaling $26.3 million will help establish seven Centers of Cancer Nanotechnology Excellence.

Power3 Medical Products, Inc. has discovered a group of breast cancer protein biomarkers in preliminary studies of blood serum.

Invitrogen will utilize a variety of its proteomics technologies including its ProtoArray™ protein microarrays and extensive protein and antibody collections.

Ipsogen will collect samples from clinical trials and will perform sample processing and pathology analysis, while Genaissance will perform genotyping and data analysis.